What is the price target for GALT stock?
7 analysts have analysed GALT and the average price target is 11.22 USD. This implies a price increase of 387.83% is expected in the next year compared to the current price of 2.3.
GALECTIN THERAPEUTICS INC (GALT) Forecast, Price Target & Analyst Ratings
NASDAQ:GALT • US3632252025
Current stock price
2.3 USD
-0.13 (-5.35%)
At close:
2.26 USD
-0.04 (-1.74%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GALECTIN THERAPEUTICS INC (GALT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 13, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.06
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.22
Upside
+ 387.83%
From current price of $2.30 to mean target of $11.22, Based on 7 analyst forecasts
Low
$11.11
Median
$11.22
High
$11.55
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for GALT. The average price target is 11.22 USD. This implies a price increase of 387.83% is expected in the next year compared to the current price of 2.3.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
GALT was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about GALT.
In the previous month the buy percentage consensus was at a similar level.
GALT was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-02 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-12-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-05-17 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-16 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 13, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.06
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 59.20%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
GALT is expected to report earnings on 5/13/2026. The consensus EPS estimate for the next earnings is -0.06 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | ||||||||||||
| EBITDA YoY % growth | -20.07M | -21.47M -6.98% | -16.25M 24.31% | -13.6M 16.31% | N/A | N/A | N/A | N/A | -38.039M | -42.396M -11.45% | N/A 45.63% | N/A 6.64% | N/A -10.90% | N/A | |
| EBIT YoY % growth | -20.08M | -21.48M -6.97% | -16.25M 24.35% | -13.6M 16.31% | -13.44M 1.18% | -23.44M -74.40% | -30.18M -28.75% | -38.35M -27.07% | -38.072M 0.72% | -42.433M -11.45% | -20.085M 52.67% | N/A -36.10% | N/A -11.19% | N/A 1,084.41% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -0.88 | -0.75 14.77% | -0.49 34.67% | -0.38 22.45% | -0.43 -13.16% | -0.40 6.98% | -0.51 -27.50% | -0.65 -27.45% | -0.74 -13.85% | -0.76 -2.70% | -0.48 36.84% | N/A 34.13% | N/A -6.45% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 59.20% | -0.07 40.50% | -0.09 29.38% | -0.10 -27.50% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -3.978M 49.56% | -4.998M -8.35% | -5.814M -3.64% | -6.732M -11.86% |
| EBIT Q2Q % growth | -3.978M 49.63% | -4.998M -8.06% | -5.814M -38.49% | -6.732M -100.06% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
GALECTIN THERAPEUTICS INC / GALT Forecast FAQ
What is the next earnings date for GALT stock?
GALECTIN THERAPEUTICS INC (GALT) will report earnings on 2026-05-13.
What are the consensus estimates for GALT stock next earnings?
The consensus EPS estimate for the next earnings of GALECTIN THERAPEUTICS INC (GALT) is -0.06 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed GALECTIN THERAPEUTICS INC (GALT)?
The number of analysts covering GALECTIN THERAPEUTICS INC (GALT) is 7.